BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

11 articles for A Alt

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HTEBI
Bristol-Myers Squibb
Triazolopyridine ethers as potent, orally active mGluEBI
Bristol-Myers Squibb
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of thed-opioid receptor.EBI
Bristol-Myers Squibb
Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists.EBI
University Walk
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.EBI
University Walk
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.EBI
University Walk
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.EBI
Eli Lilly
GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: in vitro profile and in vivo analgesic efficacy.EBI
Centro De Investigaci�N Lilly
GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain models.EBI
Centro De Investigaci�N Lilly